On October 2, 2024, Peter Farrell, a Director at ResMed Inc (RMD, Financial), sold 2,000 shares of the company at a price of $237.2 per share. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 85,204 shares of ResMed Inc.
ResMed Inc is a company that develops, manufactures, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders. These include sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic diseases.
Over the past year, Peter Farrell has sold a total of 27,535 shares of ResMed Inc and has not made any purchases of the stock. This recent sale is part of a broader trend observed within the company, where there have been 26 insider sells and no insider buys over the past year.
The shares of ResMed Inc were trading at $237.2 on the day of the sale, giving the company a market cap of approximately $35.10 billion. The price-earnings ratio of the company stands at 34.47, which is above the industry median of 30.29.
According to the GF Value, the intrinsic value of ResMed Inc is estimated at $276.41 per share, making the stock modestly undervalued with a price-to-GF-Value ratio of 0.86.
This valuation is supported by historical multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company’s past returns and growth, and future business performance estimates from Morningstar analysts.
The insider's recent transaction could provide valuable insight for current and potential investors into the insider's perspective on the stock's current valuation and future prospects.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
